JP2001521002A5 - - Google Patents

Download PDF

Info

Publication number
JP2001521002A5
JP2001521002A5 JP2000517723A JP2000517723A JP2001521002A5 JP 2001521002 A5 JP2001521002 A5 JP 2001521002A5 JP 2000517723 A JP2000517723 A JP 2000517723A JP 2000517723 A JP2000517723 A JP 2000517723A JP 2001521002 A5 JP2001521002 A5 JP 2001521002A5
Authority
JP
Japan
Prior art keywords
krebs cycle
cycle intermediate
oxaloacetate
keto
converted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000517723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/018120 external-priority patent/WO1999021565A1/en
Publication of JP2001521002A publication Critical patent/JP2001521002A/ja
Publication of JP2001521002A5 publication Critical patent/JP2001521002A5/ja
Withdrawn legal-status Critical Current

Links

JP2000517723A 1997-10-24 1998-09-01 脳の代謝機能不全のための栄養補充剤 Withdrawn JP2001521002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6316597P 1997-10-24 1997-10-24
US60/063,165 1997-10-24
PCT/US1998/018120 WO1999021565A1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010106232A Division JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Publications (2)

Publication Number Publication Date
JP2001521002A JP2001521002A (ja) 2001-11-06
JP2001521002A5 true JP2001521002A5 (https=) 2010-01-21

Family

ID=22047375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000517723A Withdrawn JP2001521002A (ja) 1997-10-24 1998-09-01 脳の代謝機能不全のための栄養補充剤
JP2010106232A Pending JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010106232A Pending JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Country Status (7)

Country Link
US (2) US6537969B1 (https=)
EP (1) EP1032403B1 (https=)
JP (2) JP2001521002A (https=)
AT (1) ATE555780T1 (https=)
AU (1) AU760140B2 (https=)
CA (1) CA2306875C (https=)
WO (1) WO1999021565A1 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332127T1 (de) * 1994-11-08 2006-07-15 Avicena Group Inc Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE19932197A1 (de) * 1999-07-09 2001-01-18 Neudecker Birgit Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7157423B2 (en) 2001-01-12 2007-01-02 Fumapharm Ag Fumaric acid amides
UA76444C2 (en) * 2001-02-14 2006-08-15 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of its use in prevention and therapy of diseases
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
EP1475090A4 (en) * 2002-02-14 2007-08-08 Ajinomoto Kk DRUG AGAINST MITOCHONDRIAL DISEASES
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
EP1567180A4 (en) * 2002-06-04 2010-03-10 Avicena Group Inc METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
AU2003247143B2 (en) * 2002-08-01 2009-07-16 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2499170A1 (en) * 2002-09-27 2004-04-08 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
RU2360671C2 (ru) * 2003-07-01 2009-07-10 Эссентис Аб Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20060084085A1 (en) * 2004-06-16 2006-04-20 Sinclair David A Methods and compositions for modulating Bax-mediated apoptosis
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
WO2006025247A1 (ja) * 2004-08-30 2006-03-09 Kaneka Corporation ミトコンドリア賦活剤
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
JP2008524123A (ja) * 2004-12-21 2008-07-10 クリティカル ケア コネクションズ インク 治療用栄養組成物又は組合せ、及びそれらの使用方法
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2006239560B2 (en) * 2005-04-28 2010-03-25 Unilever Plc Peptides having an ace inhibiting effect
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
DE102005035917A1 (de) * 2005-07-28 2007-02-01 November Ag Verwendung von Isocitrat, Isocitronensäure oder einem Derivat davon zur Herstellung eines Medikaments
DK1909600T3 (da) * 2005-07-29 2012-07-30 Tima Foundation Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme
AU2007249847A1 (en) * 2006-05-11 2007-11-22 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US8435547B2 (en) * 2006-08-30 2013-05-07 John P. Blass Cream for stimulating mitochondrial activity in the skin
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
EP2680010A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
US20090269796A1 (en) * 2007-12-05 2009-10-29 The General Hospital Corporation Methods of detecting and treating myocardial ischemia and myocardial infarction
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
CA2884592C (en) 2012-09-19 2021-08-31 Grespo Ab Compositions for improvement of brain function
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
WO2014160423A1 (en) 2013-03-13 2014-10-02 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
US10238673B2 (en) 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
GB201411937D0 (en) 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
JP6831558B2 (ja) * 2016-08-23 2021-02-17 株式会社Ｈｂｃフナト 脳機能改善組成物
US11071722B2 (en) * 2016-09-22 2021-07-27 Alan B. Cash Method to alleviate the symptoms of PMS
JP6129395B1 (ja) * 2016-10-29 2017-05-17 誠一 荒木 ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) * 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
CA3113071A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and methods of use thereof
WO2020086733A1 (en) * 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
CN114794009A (zh) * 2021-02-05 2022-07-29 崔德斌 一种用于动物模型中诱导癌症的组合物及其用途
CN115212195B (zh) * 2022-06-17 2024-02-27 重庆医科大学 苹果酸在制备预防和/或治疗抑郁症的药物中的用途
US20250221952A1 (en) * 2025-03-14 2025-07-10 Louis Dischler Methods and compositions for large modifications of atp output by inner mitochondrial membrane latching

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) * 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
DE2502735B2 (de) * 1975-01-23 1978-11-23 J. Pfrimmer & Co, 8520 Erlangen Verwendung von Glycerophosphaten
BE867467A (fr) * 1977-04-11 1978-11-27 Dow Chemical Co Aliments pour animaux contenant de l'acide malique ou un sel de ce dernier
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
AT397201B (de) 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
DK0396069T3 (da) * 1989-05-05 1994-07-25 Asta Medica Ag Salte af azelastin med forbedret opløselighed
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
FR2709982B1 (fr) * 1993-09-15 1995-12-08 Oreal Emulsions acides stables de type huile-dans-eau et compositions les contenant.
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
JP3663213B2 (ja) * 1995-06-07 2005-06-22 チェイル ジェダン コーポレーション 薬効が増強された加工薬用人参
CZ295118B6 (cs) * 1996-08-13 2005-05-18 P. N. Gerolymatos S. A. Farmaceutický prostředek
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante

Similar Documents

Publication Publication Date Title
JP2001521002A5 (https=)
US5750572A (en) Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
US5354885A (en) Process for preparing ethyl ester of L-DOPA
JPS62190160A (ja) （−）−ベンツヒドリルスルフイニルアセトアミド及びその製法
HUT48196A (en) Process for producing benzocycloheptene derivatives and pharmaceuticals comprising such active ingredient
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
NO974163L (no) Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi
ES2070994T3 (es) Profarmaco de dopamina.
US5863939A (en) Creatine ascorbates and a method of producing them
EP0154756A1 (fr) Citrate de vinpocetine et son procédé de préparation
JPS62502749A (ja) パラメトキシ桂皮酸及びウロカニン酸のアミド、それらの製造法、それらのソ−ラ−フイルタ−としての用途及びそれらを含有する皮膚−薬理的及び化粧用組成物
WO2000002850A3 (de) Sulfonylamino-carbonsäure-n-arylamide als guanylatcyclase-aktivatoren
JPH0322993A (ja) 水溶性ｌ−チロシン誘導体およびｌ−チロシン誘導体の製造方法
CA2200208A1 (en) Method for sleep induction
DE60018194T2 (de) Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten
EP0328634A1 (en) Pharmaceutical compositions for the treatment of psoriasis
TWI356821B (en) Anti-inflammatory agents
WO1999011625A1 (en) Huperzine a derivatives
US5227513A (en) Acetylsalicyloyl-L-carnitine and process for its production
US20220000814A1 (en) Methods for treatment of prader-willi syndrome
US20040176449A1 (en) Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use.
KR100772205B1 (ko) (ｒ) 및 (ｓ)-카르니틴의 니트록시 유도체
DE60010896T2 (de) Therapeutisch und/oder ernährungsphysiologisch verbesserte derivate aktiver inhaltsstoffe und oral verabreichbare zusammensetzungen, die diese enthalten
JPS62155245A (ja) 新規なパントテニル誘導体